WNS (Holdings) Limited (NYSE: WNS), a leading provider of global Business Process Management (BPM) services, today announced that it has extended its service contract with global pharmaceutical leader GlaxoSmithKline (GSK) until December, 2020.

“We are extremely proud to renew our agreement with GSK. For more than a decade, WNS has been a trusted partner driving evidence-based decisions through high-end research and analytics services. Under the agreement with GSK, WNS has set-up a dedicated state-of-the-art Knowledge Center, driven by a team of over 600 industry experts. WNS leverages its deep Pharma domain knowledge, robust analytics capabilities and proprietary frameworks to deliver actionable business insights to GSK,” said Keshav R. Murugesh, Group CEO, WNS.

With a team of over 2,500 research and analytics professionals globally, WNS provides a wide range of analytics services to our clients across Big Data, marketing, digital, HR, and operations. These solutions leverage WNS’ deep domain expertise, proprietary frameworks and technology-enabled capabilities.